WO1998058956A2 - Methods for inducing an immune response involving prime-boost protocols - Google Patents
Methods for inducing an immune response involving prime-boost protocols Download PDFInfo
- Publication number
- WO1998058956A2 WO1998058956A2 PCT/US1998/012894 US9812894W WO9858956A2 WO 1998058956 A2 WO1998058956 A2 WO 1998058956A2 US 9812894 W US9812894 W US 9812894W WO 9858956 A2 WO9858956 A2 WO 9858956A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- seq
- virus
- peptide
- immune response
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 96
- 230000001939 inductive effect Effects 0.000 title claims description 14
- 239000000427 antigen Substances 0.000 claims abstract description 198
- 102000036639 antigens Human genes 0.000 claims abstract description 198
- 108091007433 antigens Proteins 0.000 claims abstract description 198
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 198
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 125
- 239000002671 adjuvant Substances 0.000 claims abstract description 89
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 241000700605 Viruses Species 0.000 claims description 101
- 150000007523 nucleic acids Chemical class 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 74
- 108020004707 nucleic acids Proteins 0.000 claims description 74
- 239000007924 injection Substances 0.000 claims description 36
- 238000002347 injection Methods 0.000 claims description 36
- 239000002243 precursor Substances 0.000 claims description 32
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 25
- 241000124008 Mammalia Species 0.000 claims description 19
- 239000013566 allergen Substances 0.000 claims description 17
- 244000052769 pathogen Species 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 108060008724 Tyrosinase Proteins 0.000 claims description 9
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 8
- 102000003425 Tyrosinase Human genes 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 8
- 241001430294 unidentified retrovirus Species 0.000 claims description 8
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 7
- 229930182490 saponin Natural products 0.000 claims description 7
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 6
- 241000710961 Semliki Forest virus Species 0.000 claims description 6
- 241000710960 Sindbis virus Species 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 5
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 4
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 4
- 229940037003 alum Drugs 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 62
- 230000003053 immunization Effects 0.000 abstract description 48
- 238000002649 immunization Methods 0.000 abstract description 48
- 230000037452 priming Effects 0.000 abstract description 11
- 230000001976 improved effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 132
- 108090000623 proteins and genes Proteins 0.000 description 90
- 150000001413 amino acids Chemical class 0.000 description 79
- 229940024606 amino acid Drugs 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 74
- 102000004169 proteins and genes Human genes 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 38
- 108020003175 receptors Proteins 0.000 description 38
- 239000003446 ligand Substances 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 22
- 239000013598 vector Substances 0.000 description 19
- 230000027455 binding Effects 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 210000004962 mammalian cell Anatomy 0.000 description 16
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 13
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 208000026935 allergic disease Diseases 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 230000007815 allergy Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 238000011765 DBA/2 mouse Methods 0.000 description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- -1 BAGE-1 Proteins 0.000 description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000011651 chromium Substances 0.000 description 6
- 229910052804 chromium Inorganic materials 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108010093581 aspartyl-proline Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010010995 MART-1 Antigen Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 4
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 201000006512 mast cell neoplasm Diseases 0.000 description 4
- 208000006971 mastocytoma Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940117681 interleukin-12 Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 2
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 2
- SFJUYBCDQBAYAJ-YDHLFZDLSA-N Asp-Val-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SFJUYBCDQBAYAJ-YDHLFZDLSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000228405 Blastomyces dermatitidis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100039717 G antigen 1 Human genes 0.000 description 2
- 102100039699 G antigen 4 Human genes 0.000 description 2
- 102100039698 G antigen 5 Human genes 0.000 description 2
- 101710092267 G antigen 5 Proteins 0.000 description 2
- 102100039713 G antigen 6 Human genes 0.000 description 2
- 101710092269 G antigen 6 Proteins 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 2
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 2
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 2
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 2
- 101001005716 Homo sapiens Melanoma-associated antigen 11 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102100025083 Melanoma-associated antigen 11 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100088246 Mus musculus Rpl13a gene Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- YHUBAXGAAYULJY-ULQDDVLXSA-N Pro-Tyr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O YHUBAXGAAYULJY-ULQDDVLXSA-N 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- TZNNEYFZZAHLBL-BPUTZDHNSA-N Trp-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O TZNNEYFZZAHLBL-BPUTZDHNSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 101710183681 Uncharacterized protein 7 Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100029829 28S ribosomal protein S29, mitochondrial Human genes 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000588625 Acinetobacter sp. Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- DAEFQZCYZKRTLR-ZLUOBGJFSA-N Ala-Cys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O DAEFQZCYZKRTLR-ZLUOBGJFSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 241000498253 Ancylostoma duodenale Species 0.000 description 1
- 241000243790 Angiostrongylus cantonensis Species 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101710126338 Apamin Proteins 0.000 description 1
- 241000293035 Apophysomyces Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- OSASDIVHOSJVII-WDSKDSINSA-N Arg-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N OSASDIVHOSJVII-WDSKDSINSA-N 0.000 description 1
- RWDVGVPHEWOZMO-GUBZILKMSA-N Arg-Cys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)C(O)=O RWDVGVPHEWOZMO-GUBZILKMSA-N 0.000 description 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- NUHQMYUWLUSRJX-BIIVOSGPSA-N Asn-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N NUHQMYUWLUSRJX-BIIVOSGPSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 description 1
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102000039506 BAGE family Human genes 0.000 description 1
- 108091067183 BAGE family Proteins 0.000 description 1
- 241000223838 Babesia bovis Species 0.000 description 1
- 241001455947 Babesia divergens Species 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 241000589972 Borrelia sp. Species 0.000 description 1
- 241000072669 Brachiosphaera tropicalis Species 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 101150108519 CDK4 gene Proteins 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 241001495184 Chlamydia sp. Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000873310 Citrobacter sp. Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000202828 Dermatobia hominis Species 0.000 description 1
- 241000157306 Dientamoeba fragilis Species 0.000 description 1
- 241000866683 Diphyllobothrium latum Species 0.000 description 1
- 108050003186 Disks large-associated protein 3 Proteins 0.000 description 1
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 1
- 101710164941 E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000244163 Echinococcus multilocularis Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000498256 Enterobius Species 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000701148 Equine adenovirus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001518861 Erysipelothrix sp. Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- HPAIKDPJURGQLN-KBPBESRZSA-N Gly-His-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 HPAIKDPJURGQLN-KBPBESRZSA-N 0.000 description 1
- BXDLTKLPPKBVEL-FJXKBIBVSA-N Gly-Thr-Met Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O BXDLTKLPPKBVEL-FJXKBIBVSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 241000606841 Haemophilus sp. Species 0.000 description 1
- 101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- XMAUFHMAAVTODF-STQMWFEESA-N His-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 XMAUFHMAAVTODF-STQMWFEESA-N 0.000 description 1
- VDHOMPFVSABJKU-ULQDDVLXSA-N His-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N VDHOMPFVSABJKU-ULQDDVLXSA-N 0.000 description 1
- KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- FFKJUTZARGRVTH-KKUMJFAQSA-N His-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FFKJUTZARGRVTH-KKUMJFAQSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100027640 Islet cell autoantigen 1 Human genes 0.000 description 1
- 108050004848 Islet cell autoantigen 1 Proteins 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000589268 Legionella sp. Species 0.000 description 1
- 241000222738 Leishmania aethiopica Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222734 Leishmania mexicana Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 1
- VQHUBNVKFFLWRP-ULQDDVLXSA-N Leu-Tyr-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 VQHUBNVKFFLWRP-ULQDDVLXSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 101710164436 Listeriolysin O Proteins 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 102100022742 Lupus La protein Human genes 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- SEZADXQOJJTXPG-VFAJRCTISA-N Lys-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N)O SEZADXQOJJTXPG-VFAJRCTISA-N 0.000 description 1
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000202944 Mycoplasma sp. Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000498271 Necator Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241001440871 Neisseria sp. Species 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001324821 Opisthorchis felineus Species 0.000 description 1
- 241000242726 Opisthorchis viverrini Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000593811 Paracapillaria philippinensis Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000551217 Paragonimus caliensis Species 0.000 description 1
- 241001480234 Paragonimus westermani Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 1
- WEQJQNWXCSUVMA-RYUDHWBXSA-N Phe-Pro Chemical compound C([C@H]([NH3+])C(=O)N1[C@@H](CCC1)C([O-])=O)C1=CC=CC=C1 WEQJQNWXCSUVMA-RYUDHWBXSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 1
- AQSMZTIEJMZQEC-DCAQKATOSA-N Pro-His-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O AQSMZTIEJMZQEC-DCAQKATOSA-N 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000107930 Rhyacophila mirabilis Species 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 241000606714 Rickettsia sp. Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108700012261 Rotavirus VP7 Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000293026 Saksenaea Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- 241000242683 Schistosoma haematobium Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- 241000607714 Serratia sp. Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607758 Shigella sp. Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000734094 Streptobacillus sp. Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000244177 Strongyloides stercoralis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241001112221 Toxicocladosporium hominis Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000167561 Trichomonas tenax Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710148532 Tumor rejection antigen P815A Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 1
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
- 241001125316 Ureaplasma sp. Species 0.000 description 1
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000054064 human MBP Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108010063431 methionyl-aspartyl-glycine Proteins 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008191 permeabilizing agent Substances 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- This invention relates to improved methods for inducing immune responses against antigens using a virus vector for priming immunization and antigen peptides combined with an adjuvant for booster immunization. Methods for reducing an immune response using a virus vector for priming immunization and antigen peptides without an adjuvant for booster immunization are also provided.
- the immune system of a mammal often provides the first line of defense against pathogenic organisms, as well as against tumors.
- the immune system recognizes antigens expressed by tumor cells or pathogens as foreign, i.e., "non-self. Upon recognition of a non-self antigen, an immune response is mounted against the antigen, resulting in antibodies and/or cytolytic T cells which recognize the antigen.
- the immune response of a mammal is also responsible to allergy (to antigens known as allergens) and autoimmune disease, which results from inappropriate recognition of host proteins as non-self.
- tumor associated genes Genes which are expressed in tumor cells, but not in normal counterparts, can be termed "tumor associated" genes.
- the host recognizes as foreign the products of tumor associated genes which are not expressed in normal non-tumorigenic cells.
- the expression of tumor associated genes can provoke an immune response against the tumor cells by the host.
- Tumor associated genes can also be expressed in normal cells within certain tissues without provoking an immune response. In such tissues, expression of the gene and/or presentation of an ordinarily immunologically recognizable fragment of the protein product on the cell surface may not provoke an immune response because the immune system does not "see" the cells inside these immunologically privileged tissues. Examples of immunologically privileged tissues include brain and testis.
- tumor associated genes and encoded proteins and peptides which are specifically recognized by the host immune system provides a source of immunogens for provoking an immune response against the tumor cell.
- the polypeptide products of tumor associated genes can be the targets for host immune surveillance and provoke selection and expansion of one or more clones of cytotoxic T lymphocytes (CTLs).
- CTLs cytotoxic T lymphocytes
- Other tumor antigens are encoded by differentiation antigens, introns of genes expressed in tumor cells and genes bearing point mutations in tumor cells.
- Examples of this phenomenon include proteins and fragments thereof encoded by the MAGE family of genes, the tyrosinase gene, the Melan-A gene, the BAGE family of genes, the GAGE family of genes, the RAGE family of genes, the MUM-1 gene, the CDK4 gene, and the brain glycogen phosphorylase gene.
- MAGE family of genes proteins and fragments thereof encoded by the MAGE family of genes, the tyrosinase gene, the Melan-A gene, the BAGE family of genes, the GAGE family of genes, the RAGE family of genes, the MUM-1 gene, the CDK4 gene, and the brain glycogen phosphorylase gene.
- the process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one.
- An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA”), or major histocompatibility complexes ("MHCs”), and peptides.
- HLA human leukocyte antigens
- MHCs major histocompatibility complexes
- peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10.
- T cells and complexes of HLA/peptide are restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present.
- the mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides.
- T cells recognize cellular abnormalities has also been implicated in cancer.
- PCT/US92/04354 filed May 22, 1992, published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs.
- the genes are said to code for "tumor rejection antigen precursors” or "TRAP” molecules, and the peptides derived therefrom are referred to as "tumor rejection antigens" or "TRAs”. See Traversari et al., J. Exp. Med.
- cytotoxic T lymphocytes provide an effective response against tumor cells. Therefore, immunization which increases host cytotoxic T lymphocytes specific for one or more tumor rejection antigens can reduce tumor load in the host.
- the possible modes of delivery of tumor rejection antigens for immunization of cancer patients include: peptide with adjuvant (Feltkamp et al., Eur. J. Immunol. 23:2242-2249, 1993), protein with adjuvant, autologous dendritic cells or macrophages pulsed in vitro with the peptide or protein (Ossevoort et al. J. Immunother. 18:86-94, 1995), naked DNA or RNA (Conry et al., Cancer Res.
- adenoviruses as vaccine vectors against viral diseases (Cordier et al., Gene Ther. 2:16-21, 1995) has demonstrated their ability to elicit both humoral and cellular immune responses against proteins of other viruses (Randrianarison-Jewtoukoff and Perricaudet, Biologicals 23: 145-157,1995). The safety and variety delivery of modes of adenoviruses is well established (Top et al, J. Infect. Dis. 124:148-154, 1971). Other viral vectors also have been demonstrated to be safe and effective for delivery of nucleic acids into a host.
- Mastocytoma P815 is a methylcholanthrene- induced mouse tumor. It expresses several antigens recognized by CTLs (Boon et al, J. Exp. Med. 152:1184-1193, 1980). Gene P1A, which codes for antigen P815A, is expressed in several mastocytoma tumor lines (Van den Eynde et al., J Exp. Med.173:1373-1384, 1991), but not in normal tissues with the exception of testis.
- the P815 A antigen represents a good mouse model for determining the effectiveness of immunization protocols against human tumor rejection antigens.
- Immunization of a subject generally entails a "priming” or “primary” immunization which represents the first exposure of the subject to the immunogen, followed by one or more "boost” or “booster” immunizations with the same immunogen to provoke a more powerful and long-lasting immune response.
- an immune response is often generated to immunogenic epitopes of the particular adeno virus used as a vaccine vector. This effect limits the effectiveness of adenoviruses as vaccine vectors in that the adeno virus generally may not be used for both priming and boosting immunizations.
- a difficulty with the use of adenoviruses as vaccine vectors is providing a boosting vaccination to provoke a robust and long-lasting immune response.
- a host immune system in order that a host immune system will maintain immune surveillance against tumor cells throughout life, there is a need for methods of immunization which are not limited by the host immune response against viral vectors such as adenovirus (typically neutralizing antibodies directed against the viral capsid proteins) used to immunize a subject. Further, there is a need to providing effective methods for immunizing against tumor antigens to provoke a cytotoxic T lymphocyte response in a host. There is also a need to reduce inappropriate immune responses, such as found in allergy and autoimmune disease. Reduction of host immune responses is also desirable to reduce allograft transplant rejection by the host.
- viral vectors such as adenovirus (typically neutralizing antibodies directed against the viral capsid proteins) used to immunize a subject.
- adenovirus typically neutralizing antibodies directed against the viral capsid proteins
- the invention provides improved methods of immunization using virus vectors which provoke immune responses to antigens.
- the invention includes the use of antigen peptides in adjuvant for booster immunizations. These booster immunizations provoke a more robust immune response in a greater proportion of subjects.
- the invention also includes the use of antigen peptides in a non-adjuvant carrier for booster immunizations effective in reducing an immune response against such antigens.
- the invention provides compositions and pharmaceutical preparations, contained in kit form, which enable the induction of an immune response against tumor antigens.
- methods for inducing an immune response in a mammal against an antigen comprise administering to the mammal a virus containing a nucleic acid molecule encoding the antigen or its precursor in an amount effective to generate a first immune response.
- the methods further include administering at least one booster dose comprising at least one peptide in an adjuvant, wherein the at least one peptide includes the antigen, in a combined amount effective to enhance the first immune response.
- the nucleic acid molecule encodes an antigen, or a precursor or variant of the antigen, selected from the group consisting of tumor antigens and antigens characteristic of a pathogen.
- the tumor antigen is selected from the group consisting of MAGE- 1 (SEQ ID NOs:3 and 4), MAGE-3 (SEQ ID NOs:5-7), BAGE (SEQ ID NO:8), GAGE (SEQ ID NO:9), RAGE (SEQ ID NO:10), GnT-V (SEQ ID NOs:l 1 and 12), MUM-1 (SEQ ID NO:13), Tyrosinase (SEQ ID NOs:19, 20, 22, 35 and 36), DAGE (SEQ ID NO:33) and MAGE-6 (SEQ ID NO:34).
- the tumor antigen is a MAGE-3 encoded antigen recognized by HLA-A1 and represented as SEQ ID NO:5.
- the adjuvant used in this aspect of the invention is selected from the group consisting of saponin adjuvants (e.g. QS21), preferably combined with monophosphoryl lipid A (MPL) or a derivative thereof, adjuvants based on emulsions, alum, complete and incomplete Freund' s adjuvants, and montanide.
- the adjuvant is QS21/MPL.
- the doses of virus and/or peptide can be administered by a variety of routes.
- the virus or the at least one peptide is administered by injection.
- the injection is intradermal or subcutaneous.
- the invention provides for administration of booster doses of immunogen to the mammal to enhance the first immune response to the antigen.
- at least two booster doses of the at least one peptide in an adjuvant are administered.
- four booster doses are administered.
- the virus is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses such as NYVAC, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle.
- the virus is an adenovirus.
- methods for reducing an immune response in a mammal against an antigen comprise administering to the mammal a virus containing a nucleic acid molecule encoding the antigen or its precursor, in an amount effective to generate a first immune response.
- the methods further include administering at least one booster dose comprising at least one peptide in a non-adjuvant carrier, wherein the at least one peptide includes the antigen, in an amount effective to reduce the first immune response.
- the nucleic acid molecule encodes an antigen, or a precursor or variant of the antigen, selected from the group consisting of allergens, allograft antigens and autoimmune antigens.
- the doses of virus and/or peptide can be administered by a variety of routes.
- the virus or the at least one peptide is administered by injection.
- the injection is intradermal or subcutaneous.
- the invention provides for administration of doses of antigen peptide in a non-adjuvant carrier to the mammal to reduce the immune response to the antigen or allergen.
- at least two booster doses of the at least one peptide in a non-adjuvant carrier are administered.
- four booster doses in a non-adjuvant carrier are administered.
- the virus is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle.
- the virus is an adenovirus.
- a kit comprising a first container containing an adenovirus which includes a nucleic acid molecule encoding a tumor antigen and a second container containing at least one peptide including the tumor antigen, sufficient to boost an immune response of a mammal to the tumor antigen.
- the second container further contains an adjuvant.
- the kit further comprises a third container containing an adjuvant, or further comprises instructions for administering the at least one peptide with an adjuvant.
- the adjuvant preferably is selected from the group consisting of saponin adjuvants, preferably combined with monophosphoryl lipid A or a derivative thereof, adjuvants based on emulsions, alum, complete and incomplete Freund' s adjuvants, and montanide. More preferably, the adjuvant is QS21/MPL.
- the kits of the invention can be formulated to be useful for the treatment of a range of tumors.
- the tumor antigen encoded by the adenovirus and in peptide form is selected from the group consisting of MAGE- 1 (SEQ ID NOs:3 and 4), MAGE-3 (SEQ ID NOs:5-7), BAGE (SEQ ID NO:8), GAGE (SEQ ID NO:9), RAGE (SEQ ID NO: 10), GnT-V (SEQ ID NOs:l 1 and 12), MUM-1 (SEQ ID NO:13), Tyrosinase (SEQ ID NOs:19, 20, 22, 35 and 36), DAGE (SEQ ID NO:33) and MAGE-6 (SEQ ID NO:34).
- the tumor antigen is a MAGE-3 encoded antigen recognized by HLA-A1 and represented as SEQ ID NO:5.
- compositions comprising an adenovirus including a nucleic acid which encodes a non-adenovirus antigen and an adjuvant.
- the antigen and adjuvant are as described in the foregoing aspects of the invention.
- a composition comprising a peptide antigen.
- the peptide comprises non-antigen amino acids which increase the solubility of the peptide antigen in a solvent selected from the group consisting of adjuvants and non-adjuvant aqueous solutions.
- the peptide comprises at least one N-terminal glutamic acid residue, and more preferably comprises two N-terminal glutamic acid residues.
- Fig. 1 depicts the results of the immunizations described in Example 1.
- Fig. 2 depicts the results of the immunizations described in Example 2.
- Figs. 3 and 4 depict the results of the immunizations described in Example 3.
- the invention provides methods for the use of viruses in delivering antigen precursors to subjects to provoke a first immune response and peptides in adjuvant for boosting the first immune response.
- Other methods for reducing the first immune response by administering peptides in a non-adjuvant carrier are also provided.
- the methods of the invention involve the administration of viruses encoding one or more antigens to a subject by standard modes of immunization.
- the administration of the virus vector serves as the priming immunization which induces an initial (first) immune response (the primary immune response) against the tumor antigen.
- the subsequent booster immunizations with peptide antigens in combination with adjuvant increase the responsiveness of the subject's immune system to the antigen by inducing the secondary immune response, which is characterized by the increased production of cytotoxic T lymphocytes relative to the primary immune response. This is useful for increasing a subject's immune response for the treatment of tumors and pathogens.
- Exemplary tumor associated peptide antigens that can be expressed to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, BAGE-1, RAGE-1, LB33/MUM-1, DAGE, NAG, MAGE-Xp2, MAGE-Xp3, MAGE-Xp4, tyrosinase, brain glycogen phosphorylase, Melan-A and MAGE-Cl .
- antigenic peptides characteristic of tumors include those listed in Table 1 below.
- HLA-B44 SEIWRDIDF 192-200 22
- Antigens that are characteristic of pathogens include antigens derived from viruses, bacteria, parasites or fungi.
- important pathogens include Vibrio cholerae, enterotoxigenic Escherichia coli, rotavirus, Clostridium difficile, Shigella species, Salmonella typhi, parainfluenza virus, influenza virus, Streptococcus pneumoniae, Borella burgdorferi, HIV,
- Streptococcus mutans Plasmodium falciparum, Staphylococcus aureus, rabies virus and
- Epstein-Barr virus Epstein-Barr virus.
- Viruses in general include but are not limited to those in the following families: picomaviridae; caliciviridae; togaviridae; flaviviridae; coronaviridae; rhabdoviridae; filoviridae; paramyxoviridae; orthomyxoviridae; bunyaviridae; arenaviridae; reoviridae; retroviridae; hepadnaviridae; parvoviridae; papovaviridae; adenoviridae; herpesviridae; and poxyviridae.
- Bacteria in general include but are not limited to: P. aeruginosa; E. coli; Klebsiella sp.; Serratia sp.; Pseudomonas sp.; P. cepacia; Acinetobacter sp.; S. epidermis; E. faecalis; S. pneumoniae; S. aureus; Haemophilus sp.; Neisseria sp.; N. meningitidis; Bacteroides sp.; Citrobacter sp.; Branhamella sp.; Salmonella sp.; Shigella sp.; S. pyogenes; Proteus sp.;
- Mycoplasma sp. Chlamydia sp.; Rickettsia sp.; Spirochaeta; Legionella sp.; Mycobacteria sp.; Ureaplasma sp.; Streptomyces sp.; Trichomoras sp.; and R. mirabilis.
- Parasites include but are not limited to: Plasmodium falciparum, P. vivax, P. ovale, P. malaria; Toxoplasma gondii; Leishmania mexicana, L. tropica, L. major, L. aethiopica, L. donovani; Trypanosoma cruzi, T. brucei; Schistosoma mansoni, S. haematobium, S. japonium;
- Trichinella spiralis Wuchereria bancrofti; Brugia malayi; Entamoeba histolytica; Enterobius vermiculoarus; Taenia solium, T. saginata; Trichomonas vaginatis, T. hominis, T. tenax; Giardia lamblia; Cryptosporidium parvum; Pneumocytis carinii; Babesia bovis, B. divergens, B. microti;
- Necator americanis Ancylostoma duodenale; Strongyloides stercoralis; Capillaria philippinensis; Angiostrongylus cantonensis; Hymenolepis nana; Diphyllobothrium latum; Echinococcus granulosus, E. multilocularis; Paragonimus westermani, P. caliensis; Chlonorchis sinensis; Opisthorchis felineus, O. viverrini; Fasciola hepatica; Sarcoptes scabiei; Pediculus humanus; Phthirius pubis; and Dermatobia hominis.
- Fungi in general include but are not limited to: Cryptococcus neoformans; Blastomyces dermatitidis; Ajellomyces dermatitidis; Histoplasma capsulatum; Coccidioides immitis; Candida species, including C. albicans, C tropicalis, C. parapsilosis, C guilliermondii and C. krusei;
- Aspergillus species including A. fumigatus, A. flavus and A. niger; Rhizopus species;
- Rhizomucor species Cunninghammella species; Apophysomyces species, including A. saksenaea, A. mucor and A. absidia; Sporothrix schenckii; Paracoccidioides brasiliensis;
- antigens characteristic of a pathogen include: the influenza virus nucleoprotein (residues 218-226, Fu et al., J. Virol. 71 :2715-2721, 1997), antigens from Sendai virus and lymphocytic choriomeningitis virus (An et al., J Virol.
- human papillomavirus type 16 the M2 protein of respiratory syncytial virus (residues 82-90 and 81-95, Hsu et al., Immunology 85:347- 350, 1995), the herpes simplex virus type 1 ribonucleotide reductase (Salvucci, et al., J Virol. 69:1122-1131, 1995) and the rotavirus VP7 protein (Franco et al, J Gen. Virol. 74:2579-2586, 1993).
- any modes of administration which effectively deliver the adenovirus and the peptide in adjuvant can be used according to the invention.
- preferred methods include intradermal and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., Remington 's Pharmaceutical Sciences, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier.
- the peptide antigens (and optionally the adenoviruses) preferably are administered mixed with one or more adjuvants to induce an immune response or to increase an immune response.
- An adjuvant is a substance incorporated into or administered simultaneously with antigen which potentiates the immmune response.
- Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes.
- Adjuvants of many kinds are well known in the art.
- adjuvants include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of Salmonella minnesota Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham); a pure QA-21 saponin purified from Quillja saponaria extract, QS-7, QS-17, QS-18, and QS-L1 (So et al, Mol. Cells 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol.
- MPL SmithKline Beecham
- saponins including QS21 (SmithKline Beecham)
- a pure QA-21 saponin purified from Quillja saponaria extract, QS-7, QS-17, QS-18, and QS-L1 So et al, Mol. Cells 7:178-
- the peptides are administered mixed with a combination of QS21/MPL.
- the ratio of QS21 to MPL typically will be about 1 : 10 to 10:1, preferably about 1 :5 to 5 : 1 and more preferably about 1 :1.
- QS21 and MPL will be present in a vaccine formulation in the rang of about 1 ⁇ g to about 100 ⁇ g.
- Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, Monoclonal Antibodies: Principles and Practice, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.
- cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties.
- Many cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines ⁇ Science 268: 1432-1434, 1995), IL-18 and GM-CSF.
- IL-12 interleukin-12
- peptide antigens in a non-adjuvant carrier results in a reduced immune response relative to the immune response generated by administration of a virus encoding the antigen.
- administration of peptide antigens in a non-adjuvant carrier such as phosphate buffered saline can be used to reduce a subject's immune response to such antigens. This is useful in the treatment of allergic responses and autoimmune diseases, as well as in treating allograft rejection.
- a non-adjuvant carrier is a carrier which does not potentiate the immune response of the antigen with which it is co-administered.
- Non-adjuvant carriers include phosphate buffered saline, normal saline, Ringer's solution, and other solutions which are not known to potentiate an immune response.
- Antigens that are allergens are generally proteins or glycoproteins, although allergens may also be low molecular weight allergenic haptens that induce allergy after covalently combining with a protein carrier (Remington's Pharmaceutical Sciences). Allergens include antigens derived from pollens, dust, molds, spores, dander, insects and foods. Specific examples include: the major horse allergen Equ cl (Gregoire et al., J. Biol. Chem.
- antigens characteristic of autoimmune disease include: antigens from human myelin basic protein (residues 110-118), proteolipid protein (residues 80-88), myelin-associated protein (residues 287-295, 509-517, 556-564) in multiple sclerosis (Tsuchida et al. Proc. Natl. Acad. Sci USA 91 :10859-10863, 1994), the islet cell antigen ICA69 in diabetes (Karges et al., Biochim. Biophys.
- peptide antigens can be identified according to methods used in the foregoing references which describe antigens of tumors, pathogens, allergens and autoimmune disease.
- the peptides administered according to the methods described herein can have the amino acid sequence of the naturally processed antigenic peptide (e.g. those listed in Table 1, above).
- modifications can be made to the amino acid sequence to enhance binding to HLA for presentation to a subject's immune system, while retaining the ability to induce CTLs which recognize the naturally processed peptide.
- the portions of HLA binding peptides important for binding activity are known (see, e.g., Parker et al., J. Immunol. 149:3580-3587, 1992).
- the peptides used in accordance with the invention can be prepared by any method known in the art. Typically this entails programming a peptide synthesizer with a desired amino acid sequence, providing the subunits to be incorporated into the extending peptide chain, and purifying the synthesized peptide. All of these steps are well known and practiced routinely in the art.
- the peptides thus synthesized can incorporate modified amino acids and/or modified inter-amino acid bonds, if desired, to increase stability, reduce proteolysis, or confer some other property to the peptides.
- peptides may be made by other methods, including transcription and translation of a nucleic acid which encodes such peptides.
- the virus can contain a nucleic acid which encodes one or more antigens, or precursors thereof, including the whole proteins from which the one or more antigens are derived.
- antigen embraces a naturally selected antigenic peptide presented by MHC molecules, as well as variants of the naturally selected antigenic peptide which can be prepared according to methods known in the art and disclosed herein.
- the use of a complete-protein recombinant viral vaccine may be preferable because the host alleles can select the relevant epitope or epitopes for presentation. Host epitope selection recently was demonstrated by Zhai et al (J Immunol. 156: 700-710, 1996), wherein tumor infiltrating lymphocytes recognized five different epitopes presented on the surface of cells transduced with a viral vector expressing a cancer antigen.
- a viral vaccine which expresses only a portion of a gene which does not encode a functional protein, e.g., a antigen or antigen precursor, may be preferably where it is suspected that the protein may have deleterious effects. Expressing only a portion of the gene permits vaccination against an antigen without concomitant expression of a complete functional gene product in the cells which the vector has infected.
- the virus vector for expressing a nucleic acid encoding an antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle.
- replication-defective adenoviruses e.g., Xiang et al., Virology 219:220-227, 1996; Eloit et al., J Virol 7:5375-5381, 1997; Chengalvala et al., Vaccine 15:335-339, 1997)
- Venzuelan equine encephalitis virus (Davis et al., J Virol. 70:3781-3787, 1996), Sindbis virus (Pugachev et al., Virology 212:587- 594, 1995),
- the virus vector is an adenovirus.
- the term adenovirus also embraces an adenovirus genome containing exogenous genetic material which encodes a tumor antigen , i.e. an unencapsidated adenovirus.
- exogenous genetic material refers to a nucleic acid molecule (e.g., nucleic acid or oligonucleotide), either natural or synthetic, that is not naturally found in an adenovirus.
- the "exogenous genetic material” is a gene or fragment thereof which encodes an antigen or precursor thereof that can, if necessary, be processed into one or more antigens.
- the exogenous genetic material can encode more than one antigen, as in a "polytope" nucleic acid.
- the genome of an adenovirus is composed of a linear double stranded DNA approximately 36 kilobases in size.
- the genome comprises, in particular, an inverted repeat sequence (ITR) at each end, an encapsidation sequence (Psi), as well as early genes and late genes.
- ITR inverted repeat sequence
- Psi encapsidation sequence
- the main early genes are contained in the El, E2, E3, and E4 regions. Among these early genes, those contained in the El region are needed for viral propagation, i.e., replication.
- the main late genes are contained in the Ll - L5 regions.
- adenovirus genomes are known and have been deposited in nucleotide sequence databases.
- the genome of the adenovirus type 5 has been completely sequenced and is accessible via GenBank accession number M73260.
- portions or even whole genomes of other adenovirus types have also been sequenced and deposited in databases.
- the nucleic acid encoding a tumor rejection antigen or precursor thereof preferably is inserted into a region of the adenovirus genome which is not essential to the production of replication-defective recombinant adenoviruses.
- the nucleic acid preferably is not inserted into regions which contain adenovirus genes encoding proteins which are not easily supplied in trans.
- the nucleic acid preferably is inserted into the El region, which can be complemented (supplied in trans) by an adenovirus encapsidation cell line such as 293 cells.
- nucleic acid examples include the E3 region, which is not required for production of replication-defective recombinant adenoviruses, and the E4 region, mutation of which can be complemented by co-transduction with a helper virus or plasmid or by infection of a suitable complementary cell line. Other sites also may be used as will be apparent to one of ordinary skill in the art.
- access to the nucleotide sequences of adenovirus genomes enables a person skilled in the art to identify regions of the adenovirus genome suitable for insertion of the nucleic acid encoding a tumor injection antigen precursor.
- the replication-defective recombinant adenoviruses of the invention can be prepared by any technique known to the skilled artisan (Levrero et al., Gene 101:195 (1991), EP 185 573; Graham, EMBO J. 3:2917 (1984)). Generally, adenoviruses are produced by transfection of a recombinant adenovirus genome into an encapsidation cell line. Where several nucleic acids supply different portions of a replication-defective recombinant adenovirus genome, the several nucleic acids can be cotransduced into the encapsidation cell line.
- the process of forming a replication-defective adenovirus genome involves one or more steps of homologous recombination between the different nucleic acids transduced into the encapsidation cell line, in order to generate the recombinant adenovirus genome.
- Generation of adenoviruses by homologous recombination is exemplified in the examples. After assembly of a complete adenovirus genome (or introduction by transduction a complete adenovirus genome), the adenovirus is assembled by encapsidation of the adenovirus genome with adenovirus coat proteins.
- the nucleic acids assembled to prepare a complete replication-defective adenovirus genome can be prepared by any method known in the art.
- an adenovirus genome can be isolated and then modified in vitro by standard methods of molecular biology (see, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al, eds., John Wiley & Sons, Inc., New York).
- the modified adenovirus genome so obtained optionally can be isolated and used to transfect an encapsidation cell line.
- Another technique is based on the use of a plasmid carrying a portion of the genome of the recombinant adenovirus, which plasmid is co-transduced with an adenovirus supplying the missing portions of the genome.
- a complete recombinant adenovirus genome is formed by homologous recombination in the transduced cell line.
- Other possibilities include the use of prokaryotic plasmids to prepare the recombinant adenovirus genome, followed by transduction of the plasmids into an adenovirus encapsidation cell line.
- the adenovirus encapsidation cell line useful for preparation of recombinant adenoviruses is capable of accepting the nucleic acids described above and preferably contains sequences capable of complementing the replication-defective adenovirus genome to permit production of recombinant adenoviruses.
- sequences capable of complementing the defective portions of the adenovirus genome are integrated into the genome of the cell to avoid recombination with the adenovirus genome.
- the human embryonic kidney cell line 293 (Graham et al. J. Gen. Virol. 36:59, 1977) contains integrated in its genome the left- hand portion of the genome of a type 5 adenovirus.
- Other cell lines capable of complementing El and E4 functions are described in published PCT applications Nos. WO94/26914 and WO95/02697.
- adenoviruses are replication-defective due to mutation of an adeno viral gene or genes essential for adenoviral replication.
- a "replication-defective" adenovirus is one which is incapable of replicating autonomously in the target cell.
- the genome of a replication-defective adenovirus used in the context of the present invention contains mutations or deletions of at least the sequences needed for replication of the adenovirus in the infected cell.
- Such sequences are well known to those of ordinary skill in the art, and include portions of the El, E3, and E4 regions of the adenovirus genome. Such regions can be removed in whole or in part, rendered non-functional by mutation, or replaced by other nucleic acid sequences, in particular, a nucleic acid encoding a tumor-rejection antigen precursor.
- the replication-defective adenovirus retains the portions of its genome which are required for encapsidation of the adenovirus genome to form an adenovirus particle.
- the replication-defective adenoviruses of the invention include the inverted repeat sequences (ITRs), a sequence permitting encapsidation, and the nucleic acid encoding a tumor rejection antigen precursor.
- Replication-defective adenoviruses can contain a modified El region which _. _
- the El region is deleted in whole or in part, particularly the portion containing open reading frame 3 (ORF3) and open reading frame 6 (ORF6).
- the adenovirus genome used in the invention is derived from a serotype which does not exert pathogenic effects in humans.
- Preferred adenovirus serotypes for use in the invention include adenovirus type 2 (Ad2) and adenovirus type 5 (Ad5).
- Ad2 adenovirus type 2
- Ad5 adenovirus type 5
- Useful adenoviruses can be prepared by modification of the genome of a pathogenic adenovirus by art-standard recombinant DNA techniques (see, e.g., Molecular Cloning: A Laboratory Manual, J.
- adenoviruses useful in the invention include those of non-human origin (see, e.g., PCT application W094/26914)
- the adenoviruses described herein are useful for delivering a nucleic acid encoding an antigen or precursor thereof, optionally a whole protein, into a mammalian target cell for ex vivo and in vivo immunotherapy.
- the adenoviruses of the invention are useful for delivering to antigen presenting cells nucleic acid molecules that encode antigen precursors, which can be processed by the antigen presenting cells into one or more antigens, e.g., tumor rejection antigens, and presented at the cell surface to enhance the immune system response of the mammalian recipient to the specific antigen.
- only the antigen peptide is expressed by a recombinant adenovirus.
- expression of a tumor antigen peptide by an adenovirus is effective for inducing an immune response against the peptide.
- Peptides which are larger than the tumor antigen peptides can also be used provided that the larger peptide, when expressed in a host cell, is processed to a peptide which can be presented to the immune system by HLA molecules of the host.
- nucleic acids encoding a series of epitopes are used according to the invention.
- the epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., Proc. Natl. Acad. Sci. USA 92:5845-5849, 1995; Gilbert et al., Nature Biotechnol. 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired.
- the polytope is processed to generated individual epitopes which are recognized by the immune system for generation of immune responses.
- peptides derived from the MAGE-1 polypeptide, and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes can be combined with peptides from other tumor rejection antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes".
- Exemplary tumor associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including those provided above (e.g., MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, BAGE-1, RAGE-1, LB33/MUM-1, DAGE, NAG, MAGE-Xp2, MAGE-Xp3, MAGE-Xp4, tyrosinase, brain glycogen phosphorylase, Melan-A, and MAGE-Cl).
- the peptide antigens are derived from human polypeptides. Additional peptide antigens and nucleic acids encoding them will be known to one of ordinary skill in the art. One of ordinary skill in the art can prepare polypeptides comprising one or more of the foregoing peptides, or nucleic acids encoding such peptides, according to standard procedures of molecular biology.
- polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping).
- the polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.
- the peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., Proc. Natl. Acad. Sci USA 92(13):5845-5849, 1995; Gilbert et al., Nature Biotechnol. 15(12):1280-1284, 1997; Thomson et al., J. Immunol. 157(2):822-826, 1996; Tam et al., J. Exp. Med. 171(l):299-306, 1990).
- polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs.
- polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response. It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient or test subject.
- Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Similarly, polytopes can be prepared which include multiple peptides representing a plurality of epitopes of other antigens, e.g., derived from pathogens.
- Polytopes can be introduced to a patient in need of such treatment via the use of nucleic acid delivery systems described herein, or as polypeptide structures representing booster doses.
- the systems also can be tested in human clinical trials.
- auxiliary nucleic acids are inserted into the virus genome to enhance or otherwise improve the therapeutic efficacy of the immunotherapy in treating the condition.
- auxiliary nucleic acids for delivery to the mammalian target cell include nucleic acids encoding tumor suppressor genes, nucleic acids encoding antisense mRNA or encoding catalytic RNA that inactivate oncogenes, and nucleic acids that render a target tumor cell more susceptible to an administered drug (e.g., suicide genes encoding, for example, thymidine kinase).
- Auxiliary nucleic acids also include nucleic acids encoding cytokines that enhance a naturally occurring anti-tumor immunity. Exemplary cytokines which have this function include, e.g., IL-4, TNF, IL-2, IL-12, IL-18 and GM-CSF.
- nucleic acids encoding costimulatory molecules such as B7-1 and B7-2 can be used (Chamberlain et al., Cancer Res. 56:2832-2836, 1996; Townsend and Allison, Science 259:368-370, 1993; Chen et al., J. Exp. Med. 179:523-532, 1994).
- nucleic acid molecule encoding an antigen or antigen precursor is inserted into the virus genome using conventional recombinant DNA techniques, as exemplified in the Examples. See also, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York.
- a nucleic acid molecule encoding a tumor rejection antigen precursor is inserted into well-defined restriction sites in a portion of the adenovirus genome not required for transcription or translation of the nucleic acid molecule.
- the nucleic acid molecule encoding a tumor rejection antigen precursor preferably is inserted in one of the El, E3 or E4 regions of adenovirus.
- the virus genome further includes a regulatory sequence, e.g., a promoter region (also referred to as a "promoter”), that is operably coupled to the nucleic acid molecule encoding an antigen or antigen precursor.
- the regulatory sequence controls the expression of the nucleic acid molecule encoding an antigen or antigen precursor in the target cell.
- a nucleic acid molecule encoding an antigen precursor (the "coding sequence") and regulatory sequences are said to be “operably” joined when they are covalently linked in such a way as to place the transcription or the expression of the coding sequence under the influence or control of the regulatory sequences.
- two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
- a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.
- regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 3' or 5' non-transcribed non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, CAAT sequence, and the like.
- 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.
- Regulatory sequences can also include enhancer sequences or upstream 5' or downstream 3' transcriptional regulatory sequences as desired.
- Exemplary promoters that are useful in the invention include constitutive promoters and regulatable promoters (e.g., cell lineage specific promoters, inducible promoters).
- Exemplary constitutive promoters include promoters derived from cytomegalovirus, a long terminal repeat (LTR) of retroviruses, e.g., Rous sarcoma virus or Moloney murine leukemia virus, and adenovirus El A promoter, an adenovirus MLP promoter and a SR ⁇ promoter.
- tissue or cell specific transcriptional regulatory sequences can be derived from the genes encoding the following proteins: tyrosinase, lipoprotein lipase, albumin, muscle creatine kinase, keratin (K14/K10), globin gene cluster, immunoglobulin heavy chain gene cluster, and involucrin.
- liver-specific promoters such as the albumin promoter/enhancer
- albumin promoter/enhancer also have been described (see, e.g., PCT application number PCT/US95/11456, having international publication number WO96/09074, entitled "Use of a Non-mammalian DNA Virus to Express an Exogenous Gene in a Mammalian Cell,” hereinafter W096/09074, and the references cited therein).
- the alpha-feto protein promoter can be used to effect expression of a therapeutic polynucleotide(s) in liver tumor cells (but not normal liver cells) for treating liver cancer.
- inducible promoters are described in the following references: Science 268:1786 (1995); TIBS 18:471 (1993); PNAS 91 :3180 (1994); PNAS 90:1657 (1993); PNAS 88:698 (1991); Nature Biotechnol. 14:486 (1996); and PNAS 93:5185 (1996).
- An exemplary repressible promoter, the tetracycline repressible system, is described in PNAS 89:5547 (1992).
- Other constitutive, tissue-specific, inducible and repressible promoters will be known by those of skill in the art and thus are not listed here.
- the viruses optionally contain one or more sequences that are suitable for use in the identification of cells that have or have not been transduced.
- Transduction refers to the introduction of the virus genome into the target cell. Markers to identify cells that have been transduced include, for example, genes encoding proteins that increase or decrease resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes having activities that are detectable by standard assays known in the art and genes which detectably (e.g. visibly) affect the phenotype of the transduced target cells, hosts, or plaques.
- Exemplary genes that are suitable as markers include a lacZ gene, a chloramphenicol acetyltransferase gene, an alkaline phosphatase gene, a luciferase gene, and a green fluorescent protein gene.
- the modified viruses of the invention can be delivered to a cell of a subject by methods known to those of ordinary skill in the art.
- a subject is injected with the modified virus which includes a nucleic acid encoding an antigen against which modulation of an immune response is desired.
- other methods are also available to the skilled artisan, particularly in cases in which the virus is modified to recognize a certain receptor on the cell of a subject.
- Methods for delivering whole encapsidated virus include injection, inhalation, ingestion, in vitro infection of cells, and the like.
- a recombinant adenovirus genome in association with an adenovirus coat i.e.
- the cell in the form of an infectious encapsidated adenovirus
- the cell can be contacted with the adenovirus, and the adenovirus genome can be delivered by receptor-mediated endocytosis via binding of an adenovirus coat protein to a cellular receptor.
- Methods for delivering non-encapsidated virus include the foregoing methods and also methods for delivery of nucleic acids to cells familiar to those of skill in the art of molecular biology.
- the nucleic acid when delivering a recombinant adenovirus genome without any associated coat protein, the nucleic acid can be introduced into a cell by transduction using a standard technique such as electroporation, liposome transfection, calcium phosphate precipitation, or a commercially available technology such as the Tfx-50 transfection reagent (Promega Corp., Madison, WI).
- a standard technique such as electroporation, liposome transfection, calcium phosphate precipitation, or a commercially available technology such as the Tfx-50 transfection reagent (Promega Corp., Madison, WI).
- the virus can be modified to target it to certain cell type or tissue.
- Targeting of a virus to a particular cell or tissue can be accomplished by choice of an appropriate ligand/receptor pair which is specific for the cell or tissue, and incorporation of the ligand into the virus coat. Methods for attaching a ligand to a viral coat are disclosed below.
- Exemplary receptors include hepatic receptors (hyaluronic acid, collagen, N-terminal propeptide of collagen type III, mannose/N-acetylglucosamine, complement, asialoglycoprotein, tissue plaminogen activator, low density lipoprotein, insulin, ceruloplasmin, enterokinase, carcinoembronic antigen, apamin, galactose/lactose); growth factor/cytokine receptors (hepatocyte growth factor, epidermal growth factor, insulin-like growth factor I, II, interleukin- l ⁇ / ⁇ , interleukin-2, IL-7, IL-4, ⁇ -interferon, ⁇ -interferon, keratinocyte growth factor, TNF-R p55); hormone receptors (prolactin, thyroglobulin, growth hormone, insulin, glucagon, leutinizing hormone, human choriogonadotrophic hormone); nerve cell receptors (neurotensin); anti
- novel ligands can be identified using phage display procedures such as those described in Hart, et al, J. Biol. Chem. 269:12468 (1994). While such filamentous phages could, of course, never be used to deliver genetic material to a cell (because they are single stranded), this methodology is potentially very useful in the discovery of novel receptor ligand interactions. For example, Hart et al. report a filamentous phage display library for identifying novel peptide ligands for mammalian cell receptors.
- phage display libraries using, e.g., Ml 3 or fd phage are prepared using conventional procedures such as those described in the foregoing reference.
- the libraries display inserts containing from 4 to 80 amino acid residues.
- the inserts optionally represent a completely degenerate or a biased array of peptides.
- Ligands that bind selectively to a particular type of target cell are obtained by selecting those phages which express on their surface a ligand that binds to the target cell of interest. These phages then are subjected to several cycles of reselection to identify the peptide ligand- expressing phages that have the most useful binding characteristics.
- phages that exhibit the best binding characteristics are further characterized by nucleic acid analysis to identify the particular amino acid sequences of the peptides expressed on the phage surface and the optimum length of the expressed peptide to achieve optimum binding to the target mammalian cell.
- peptide ligands can be selected from combinatorial libraries of peptides containing one or more amino acids. Such libraries can further be synthesized which contain non-peptide synthetic moieties which are less subject to enzymatic degradation compared to their naturally-occurring counterparts. These novel ligands can be attached to the virus surface to deliver the virus to the particular target cell of interest.
- At least four procedures are known to those of skill in the art for attaching a ligand to the surface of an virus. These include (1) chemical modification of the virus surface (e.g., galactosylation, cross linking reactions); (2) modification of the virus genome to express a ligand on the virus surface (e.g., a fusion protein formed between the ligand and a functional viral packaging protein); (3) selective binding of a ligand (e.g., a monoclonal antibody, a polyclonal antibody, or functionally active fragments thereof containing an Fc domain) to an virus surface antigen to mediate targeting of the virus to cells that express an Fc receptor on their surface; and (4) modification of the virus genome to form an avidin- labeled virus intermediate to which a biotinylated ligand (e.g., antibody) can be attached.
- chemical modification of the virus surface e.g., galactosylation, cross linking reactions
- modification of the virus genome to express a ligand on the virus surface
- the viruses of the invention are contacted with the target cell under conditions to permit selective binding of the ligand on the surface of the virus to the receptor on the surface of the target cell and to allow the virus to enter the target cell.
- Conditions which permit the binding of a receptor to its cognate ligand are the physiological conditions (e.g., the particular pH, ionic strength, viscosity) at which the ligands and receptors are known to bind to one another in vivo and the conditions at which the ligands and receptors are known to bind to one another in vitro, - lb - such as in receptor assays for determining the presence of a ligand in, for example, a biological fluid.
- the conditions that allow the target cell to live and transcribe the nucleic acid molecule encoding a tumor rejection antigen precursor are the same conditions that permit selective binding of the ligand to the receptor and that allow the virus to enter the target cell.
- the conditions that allow the cell to transcribe the nucleic acid molecule further include the addition of an inducer that activates an inducible promoter to induce transcription and translation of the nucleic acid molecule.
- optimum conditions for inducing the transcription and translation of a nucleic acid molecule encoding a tumor rejection antigen precursor that is under the control of a particular inducible promoter can be determined by one of ordinary skill in the art using no more than routine experimentation.
- conventional tissue culture conditions and methods are used to sustain the mammalian cell in culture.
- the mammalian cell can be allowed to live on a substrate containing collagen, e.g., type I collagen, or a matrix containing laminin, such as described in PCT application number PCT/US95/11456, having international publication number WO96/09074, entitled "Use of a Non-mammalian DNA Virus to Express an Exogenous Gene in a Mammalian Cell," and the references cited therein.
- contacting in reference to the virus and the target cell, refers to bringing the virus into sufficiently close proximity to the target cell to permit the receptor on the target cell to selectively bind to the ligand on the virus. Such conditions are well known to those of ordinary skill in the art.
- the modified virus can be contacted with the targeted mammalian cell in vitro, for example, for ex vivo immunotherapy or in vivo for in vivo immunotherapy.
- a "mammalian target cell” refers to a mammalian cell (preferably, a human cell) which contains on its surface a receptor for the ligand that is contained on the surface of the virus (which may be the natural ligands of the virus which allow entry of the virus into cells of its host range).
- a mammalian cell can be targeted in accordance with the methods described herein.
- the cell may be a primary cell or may be a cell of an established cell line. Exemplary cell types that can be targeted are provided above in connection with receptor/ligand pairs.
- the mammalian cell is a cell which contains the immune system components required for the induction of an immune response in the host.
- the target cell subsequently can be introduced into the mammal (e.g., into the portal vein or into the spleen) if desired.
- expression of the nucleic acid molecule encoding an antigen or antigen precursor is accomplished by allowing the cell to live or propagate in vitro, in vivo, or in vitro and in vivo, sequentially.
- the invention is used to express an antigen or antigen precursor in more than one cell, a combination of in vitro and in vivo methods are used to introduce the nucleic acid molecule encoding the antigen or antigen precursor into more than one mammalian cell.
- the cells are removed from a subject and a nucleic acid (i.e. adenovirus genome) is introduced into (i.e., transduced) the cells in vitro.
- a nucleic acid i.e. adenovirus genome
- the transduced cells are expanded in culture before being reimplanted into the mammalian recipient.
- the procedure for performing ex vivo gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents.
- ex vivo immunotherapy involves the introduction in vitro of a nucleic acid which encodes an antigen into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject to stimulate an immune response.
- the nucleic acid which encodes an antigen is under the operable control of regulatory elements which permit expression of the nucleic acid which encodes an antigen in the genetically engineered cell(s).
- the target cells are not removed from the patient. Rather, the nucleic acid molecule encoding a tumor rejection antigen precursor is introduced into the cells of the mammalian recipient in situ, i.e., within the recipient.
- the methods disclosed herein are practiced by using a modified virus, e.g.
- a replication-defective adenovirus as described herein, in place of the gene therapy vectors disclosed in the prior art in the procedures currently used for administering these vectors (or cells containing these vectors) to the subjects. Such procedures are known to those of skill in the art of human gene therapy.
- the virus or virus genome is administered to the mammalian recipient, for example, intravascularly, intraluminally (introduction of the adenovirus into body cavities and lumens, such as the genital-urinary tract, gastrointestinal tract, trachea- bronchopulmonary tree or other internal tubular structures), direct injection into a tissue (e.g., muscle, liver), topical application (e.g., eye drops or aerosol application to mucosal surfaces), or intracavitarily (e.g., intraperitoneally or intrathecally (introduction into the cerebrospinal fluid)).
- a tissue e.g., muscle, liver
- topical application e.g., eye drops or aerosol application to mucosal surfaces
- intracavitarily e.g., intraperitoneally or intrathecally (introduction into the cerebrospinal fluid)
- the ligand/receptor-mediated delivery of the modified virus is the predominant mechanism for targeting delivery of the virus to a particular cell type
- delivery to the target cell can further be modulated by regulating the amount of virus administered to the mammalian recipient and/or by controlling the method of delivery.
- intravascular administration of the virus to the portal vein or to the hepatic artery can be used to facilitate targeting the virus to a liver cell.
- the modified virus can be administered to the mammalian recipient using the same modes of administration that currently are used for adenovirus-mediated gene therapy in humans.
- Such conditions are adequate for contacting the virus and the target cell under conditions to permit selective binding of a ligand on the surface of the virus to a receptor on the surface of the target cell and to allow the virus to enter the target cell.
- the virus can be administered to the mammalian recipient by intra- vascular injection, intra-organ introduction by, for example, injection into the organ or contacting the virus with the organ in the presence of a tissue permeabilizing agent; and introduction of the virus into body cavities or lumens.
- Mammalian cells which have been transduced with the virus ex vivo can be introduced into the mammalian recipient using the known methods for implanting transduced cells into a human for gene therapy. See, e.g., U.S. Patent No. 5,399,346 ("Gene Therapy") issued to Anderson et al; PCT International application no. PCT/US92/01890 (Publication No. WO 92/15676, "Somatic Cell Gene Therapy", claiming priority to U.S. Serial No.
- the invention is not limited in utility to human immunotherapy, but also provides a method for assessing the effects of immunosuppressive agents in mammalian models such as primates, pigs, sheep, dogs, rodents, and cows. The invention also provides an improved method for testing the effectiveness of antigen peptides as booster agents in a mammal.
- a virus containing a nucleic acid molecule encoding an antigen can be administered to a group of mammals as a priming immunization.
- a series of peptides can then be administered to the group of mammals as booster immunizations.
- the series of peptides can include variants of recognized antigenic peptides and the immune response of each of these variants can thus be assessed to determine the optimal amino acid sequence of immune response boosting peptides. Modifications to the peptides can be made based on known parameters of HLA binding affinity described above, or randomly, and tested for immunogenic potential by the same methodology.
- the invention provides other compositions and kits which are useful for practicing the above-described methods.
- kits which contain (a) an adenovirus containing a nucleic acid molecule that encodes a tumor rejection antigen or precursor thereof; and (b) a peptide optionally in adjuvant for administering as booster immunization(s), and optionally, (c) a separate container of adjuvant. Instructions for the use of the adenovirus and peptide(s) can also be included.
- the components of the kit are sufficient, when administered to a subject, to induce an immune response in the subject against the antigen encoded by the nucleic acid and represented by the peptide.
- the adenovirus optionally is contained in a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- the particularly preferred adjuvant is QS21/MPL.
- compositions used in the foregoing methods should be sterile and contain a therapeutically effective amount of the modified viruses for priming an immune response (or target cells containing such viruses) in a unit of weight or volume suitable for administration to a patient.
- an effective amount of a virus encoding an antigen means an amount which is sufficient to induce a first immune response.
- the first immune response can be measured by determining the activity of cytotoxic T lymphocytes. Methods for measuring cytotoxic T lymphocyte activity include measurement of tumor necrosis factor release by the cytotoxic T lymphocytes and measurement of chromium release as exemplified in the examples. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the first immune response for comparison with the immune response following peptide administration.
- the peptide compositions for booster immunizations should also be composed of pharmaceutically acceptable components and administered in effective amounts.
- an effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein.
- this may involve the stimulation of a humoral antibody response resulting in an increase in antibody titer in serum, a clonal expansion of cytotoxic lymphocytes, or some other desirable immunologic response.
- the absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual patient parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
- an effective amount of a peptide antigen means an amount sufficient to modulate the first immune response.
- an effective amount is a combined amount of peptide and adjuvant which increases the immune response relative to the first immune response generated by administration of the virus encoding the antigen.
- an effective amount is an amount which decreases the immune response relative to the first immune response generated by administration of the virus encoding the antigen.
- the increase or decrease of the immune response can be measured as above for the first immune response; preferably the immune response is measured by the determining the activity of cytotoxic T lymphocytes by measuring tumor necrosis factor release or chromium release from cytotoxic T lymphocytes.
- An increase in the activity of the cytotoxic T lymphocytes relative to the activity of the cytotoxic T lymphocytes present after the first immune response indicates that the peptide in adjuvant enhanced the first immune response.
- a decrease in the activity of the cytotoxic T lymphocytes relative to the activity of the cytotoxic T lymphocytes present after the first immune response indicates that the peptide in a non-adjuvant carrier reduced the first immune response.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.
- physiologically acceptable refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.
- the doses of antigen-encoding virus and peptide administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the particular antigen used for immunization and the desired period of treatment.
- the viruses of the invention are formulated and administered in the form of doses between 10 4 and 10 14 plaque forming units (pfu), and preferably 10 6 to 10 10 pfu. Plaque forming units correspond to the infectious power of an amount of virus.
- the pfu value of an adenovirus solution can be determined by infecting a suitable cell culture and measuring, after a time sufficient to allow adenovirus- mediated cell lysis, the number of plaques of infected cells. This and other techniques for determination of the pfu value of an adenovirus stock are known to those of ordinary skill in the art.
- booster doses of peptide are formulated and administered in doses between 50 ng and 50 mg, and preferably between 5 ⁇ g and 500 ⁇ g. Such doses can be administered by injection in one or more sites in the subject.
- An example of a preferred immunuzation protocol is as follows.
- a patient can be immunized with peptides for boosting an immune response by injection intradermally (i.d.), subcutaneously (s.c.) or imtramuscularly (i.m.) in 1 to 4 sites of the arms and/or legs of the patient using amounts of peptides ranging from 10 to 300 ⁇ g.
- the patient is immunized 3 to 4 times with an interval of 1 month between immunizations.
- the volumes for such immunizations usually are 100 to 200 ⁇ l for the i.d. route, and 0.5 ml for the s.c. and i.m. routes. Greater amounts of peptide, as indicated above, can be administered.
- DBA 2J female mice were derived from an inbred colony (Iffa Credo, Lyon, France) and raised in specific pathogen-free conditions in our animal facilities. The mice were between 8 and 12 weeks old. Mice were immunized as indicated with a total amount of 10 7 or 10 8 plaque- forming units (pfu) of recombinant adenovirus injected intradermally (i.d.) into each ear in 50 ⁇ l of phosphate buffered saline (PBS), or intraperitoneally (i.p.) with 10 9 pfu in 200 ⁇ l of PBS.
- PBS phosphate buffered saline
- Pl.aza r is a subclone of mastodytoma P815.
- Antigen-loss variant Pl.ist A B _ designated PI.204, is a subclone of mastocytoma P815 obtained from a mouse injected with this P815 cell line. (Uyttenhove et al. J. Exp. Med. 157:1040-1052, 1983).
- Transfectant clone L1210.P1A.B7.1 was obtained by electroporation of L1210.P1A with a cDNA encoding the murine B7.1 antigen cloned in plasmid pEFBOS (Gajewski et al. J. Immunol. 154:5637-5648, 1995).
- the control L1210.P1 A.C clone was obtained by transfecting L1210.P1 A with plasmid pEFBOS.
- BALB/c 3T3 is a fibroblastic cell line and CMS-5 is a carcinoma of BALB/c origin.
- Dap-L d is a transfected derivative of DAP-3, a subclone of L fibroblastic H-2 k cell line. These cell lines were cultured in Petri dishes (Falcon 1001, Oxnard, CA) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % FCS. Cells were incubated at 37 °C in an 8 % C0 2 atmosphere.
- DMEM Dulbecco's modified Eagle's medium
- CTL clone CTL-P1 :5 a clone specific for antigen P815A, was cultivated in 1 ml cultures containing
- Pl.aza r cells are killed in medium supplemented with HAT (10 "4 M hypoxanthine, 3.8 x 10 "7 M aminopterin, and 1.6 x 10 "5 N deoxythymidine).
- the CTL culture medium was DMEM supplemented with L-arginine (5.5 x 10 "4 M), L-asparagine (2.4 x 10 “4 M), L-glutamine (1.5 x 10 "3 M), glucose (3.5 g/1), HEPES (10 "2 M), 2-mercaptoethanol (5 x 10 "5 M) and 10 % FCS (this is referred to as MLTC medium).
- cultures contain 50 % of supernatant from secondary mixed lymphocyte culture (MLC) as a source of cytokines. Cultures were maintained in 24 well plates at 37 °C in an 8 % C0 2 atmosphere (Uyttenhove et al., 1983).
- MLTC Mixed lymphocyte-tumor culture
- Spleen cells (5 x 10 6 ) from mice injected two weeks previously with Adeno.PlA or Adeno. ⁇ gal were stimulated with 2 x 10 5 irradiated (100 Gy) L1210.P1A.C or L1210.P1A.B7.1 in 2 ml of MLTC medium.
- the cultures were maintained in 24 well plates at 37 °C for 7 days and the responder cells were then tested for cytolytic activity.
- CTL stimulation assay Adenovirus-infected cells were tested for their ability to stimulate the production of TNF by CTL. Briefly, 2000 CTL were added to microwells containing 15,000 target cells in 100 ml in MLTC medium. After 24 hr, 15 ml of the supernatant were collected and incubated with 30,000 cells WEHI-164 clone 13, a TNF-sensitive cell line (Espevik and Nissen-Meyer, J. Immunol. Methods 95:99-105, 1986). The cytotoxic effect of the supernatant was determined in a MTT colorimetric assay (Hansen et al., J. Immunol. Methods 119:203-210, 1989).
- CTL-P1 :5 or MLTC responder cells were mixed at various ratios with 2,000 51 Cr-labeled target cells. After 4 hr the radioactivity was measured.
- BALB/c 3T3, CMS-5 and DAP-L d targets were incubated with effector cells for 6 to 8 hr.
- Plasmid pcD-SR ⁇ Pl A was obtained by inserting into the EcoRI site of vector pcD-SR ⁇ a 44-bp sequence (SEQ ID NO: 1 ; AATTCGCCGCCATGCTGCCTTATCTAGGGTGGCTGG TCTTCTAG), which codes for the L d -restricted peptide of murine tumor rejection antigen P815A, preceded by a Kozak consensus start sequence.
- the SR ⁇ promoter system is composed of the SV40 origin region containing an enhancer and a transcription starting point preceded by a TATA box, followed by an incomplete HTLV-1 LTR and a 16S splicing region.
- the Hindlll- Sall fragment containing the Sr ⁇ promoter, the PIA sequence and the SV40 polyadenylation signal was cloned in the pBluescript vector. It was excised by digestion with Spel-Sall and inserted into plasmid pAdeno.RSV ⁇ gal (Stratford-Perricaudet et al., J. Clin. Invest. 90:626-630, 1992) digested by the same enzymes to remove the RSV ⁇ gal cassette while retaining the adenoviral sequences (see Warnier et al., 1996 for additional details).
- the recombinant adenovirus Adeno.PlA was constructed by in vivo homologous recombination in cell line 293 (Graham et al., J. Gen. Virol. 3659-72, 1977) between pAdeno.Sr ⁇ Pl A and Adeno. dl324 genomic DNA (referred to below as Adeno. def), as described (Strafford-Perricaudet et al., 1992). Briefly, 293 cells were cotransfected with 5 ⁇ g of linearized plasmid pAdeno.SR ⁇ PlA and 5 ⁇ g of the large Clal fragment of Adeno.
- the recombinant adenovirus was plaque purified and the presence of the transgene was assessed by restriction analysis of the adenoviral DNA.
- Recombinant adenoviruses were propagated in 293 cells, purified by double cesium-chloride density centrifugation and extensively dialyzed. The viral stocks were stored in aliquots with 10 % glycerol at -80 °C and titered by plaque assay using 293 cells.
- Example 1 Immunization of DBA/2 mice with Adeno.PlA and boosting with peptide.
- mice 76 DBA/2 female mice (8-12 weeks old) were immunized once with a total amount of 10 8 pfu of Adeno.PlA injected intradermally into each ear in 50 ⁇ l of PBS. After 3 weeks, 25 mice received at a two-week interval two subcutaneous injections in the two foot pads of a total amount of 50 ⁇ g of EE-Pl A peptide (SEQ ID NO:2; Glu Glu Leu Pro Tyr Leu Gly Trp Leu Val Phe) mixed with the QS21/MPL adjuvant (SmithKline-Beecham). The final volume was 100 ⁇ l (50 ⁇ l of a PBS solution of the peptide and 50 ⁇ l of QS21/MPL).
- mice The addition of two glutamic acid residues at the N-terminus of the PIA peptide allowed a higher solubility in PBS or adjuvant. Another group of 26 mice was injected in the same way with the peptide in PBS (no adjuvant). A control group of 25 mice received PBS only (no peptide).
- mice Two weeks after the second injection of the peptide, the spleens of the mice were removed and the spleen cells were tested for their capacity to induce an anti-P815A CTL response as an in vitro test of in vivo function.
- 5 x 10 6 splenocytes were restimulated in vitro in the presence of either 2 x 10 5 L1210A+B7.1 or L1210A+.C irradiated stimulating cells (100 Gy) in 2 ml of MLTC medium. The cultures were maintained in 24 well plates at 37 °C for 7 days. Their lytic activity was then tested in a chromium release assay, as described above, using 2 x 10 3 P511 or Pl .204 target cells.
- P511 is an azaguanine-resistant variant derived from P815 cells expressing P815A antigen.
- the negative control PI.204 is an antigen-loss variant which does not express the P815A antigen (Uyttenhove et al., 1983; Lethe et al., Eur. J. Immunol. 22:2283- 2288, 1992). Both target cells were mixed with a 50-fold excess of unlabeled P1.204 cells to prevent non-specific lysis.
- Each symbol seen in Fig. 1 represents the lytic activity obtained with splenocytes of one mouse. Results are expressed in the number of lytic unit/10 6 cells (L.U.) on a logarithmic scale (Warnier et al., 1996).
- mice with lytic activity up to 10 L.U. were considered double positive (++). Mice with lytic activity between 1 and 10 L.U. were scored +, between 0.2 and 1 L.U. were scored ⁇ , and equal to or below 0.2 L.U. were scored -.
- Example 2 Immunization of DBA/2 mice with Adeno.PlA followed by four booster injections of peptide.
- Example 1 We investigated the possibility of improving the results obtained in Example 1 above by increasing the number of booster injections using peptide, either in the foot pad or in loco. It was also of interest to determine if a low dose of Adeno.PlA (10 7 pfu) was sufficient to prime the mice and allow the boost effect of the peptide-adjuvant mixture. We used two doses of Adeno.PlA (10 7 and 10 8 pfu) following the same protocol of injections as described in ,, ,
- Example 1 Each group of infected animals received 50 ⁇ g of the EE-Pl A peptide mixed in QS21/MPL four times either i.d. in the ears or s.c. in the foot pad. Control groups were infected with Adeno.PlA alone or with Adeno. ⁇ gal followed by peptide in QS21/MPL. Mice were bled 15 days after the fourth injection of the peptide and peripheral blood lymphocytes (PBL) were tested for the presence of an anti-P815A CTL response.
- PBL peripheral blood lymphocytes
- the CTL response obtained is represented in Fig. 2. Focusing on the results obtained with L1210.P1A.C stimulating cells, 13 mice out of 14 (93 %) of the primed mice (10 7 or 10 8 pfu) reinjected s.c. displayed variable but positive responses against antigen P815A. One hundred percent of the mice injected i.d. showed a strong cytolytic activity. This is compared with 7 out of 16 (44 %) of control Adeno.PlA primed mice (10 8 pfu) and the 4 out of 16 (25 %) control Adeno.PlA primed mice (10 7 pfu).
- CORRESPONDENCE ADDRESS (A) ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79831/98A AU7983198A (en) | 1997-06-23 | 1998-06-19 | Improved methods for inducing an immune response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88097997A | 1997-06-23 | 1997-06-23 | |
US08/880,979 | 1997-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998058956A2 true WO1998058956A2 (en) | 1998-12-30 |
WO1998058956A3 WO1998058956A3 (en) | 1999-03-18 |
Family
ID=25377532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/012894 WO1998058956A2 (en) | 1997-06-23 | 1998-06-19 | Methods for inducing an immune response involving prime-boost protocols |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7983198A (en) |
WO (1) | WO1998058956A2 (en) |
ZA (1) | ZA985460B (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2360210A (en) * | 2000-01-14 | 2001-09-19 | Allergy Therapeutics Ltd | Sublingual vaccine formulation |
US6429287B1 (en) * | 1996-09-13 | 2002-08-06 | Ludwig Institute For Cancer Research | Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof |
WO2005002621A2 (en) * | 2003-06-17 | 2005-01-13 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
WO2006009919A2 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
WO2006071989A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
US7338670B2 (en) | 2005-04-14 | 2008-03-04 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
EP1964573A2 (en) | 1999-10-22 | 2008-09-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
US7718178B2 (en) | 1997-04-05 | 2010-05-18 | Allergy Therapeutics Limited | Allergen formulation |
US7815920B2 (en) | 1998-09-21 | 2010-10-19 | Allergy Therapeutics (UK) Ltd | Method of preparing an antigen-containing formulation |
US20120039994A1 (en) * | 2006-09-26 | 2012-02-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8206701B2 (en) * | 2001-03-16 | 2012-06-26 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US8273361B2 (en) * | 2006-09-26 | 2012-09-25 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8298549B2 (en) | 2007-07-02 | 2012-10-30 | Etubics Corporation | Sequential administration of a replication defective adenovirus vector in vaccination protocols |
US8697854B2 (en) | 2008-11-24 | 2014-04-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
US8921534B2 (en) | 2001-12-12 | 2014-12-30 | Sanofi Pasteur Limited | Enhancement of the immune response using CD36-binding domain |
US8957047B2 (en) | 2013-04-18 | 2015-02-17 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US9480740B2 (en) | 2009-06-05 | 2016-11-01 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US9895435B2 (en) | 2012-05-16 | 2018-02-20 | Immune Design Corp. | Vaccines for HSV-2 |
US10064934B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
-
1998
- 1998-06-19 AU AU79831/98A patent/AU7983198A/en not_active Abandoned
- 1998-06-19 WO PCT/US1998/012894 patent/WO1998058956A2/en active Application Filing
- 1998-06-23 ZA ZA985460A patent/ZA985460B/en unknown
Non-Patent Citations (4)
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429287B1 (en) * | 1996-09-13 | 2002-08-06 | Ludwig Institute For Cancer Research | Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof |
US8105605B2 (en) | 1997-04-05 | 2012-01-31 | Allergy Therapeutics (Uk) Ltd. | Allergen formulation |
US7718178B2 (en) | 1997-04-05 | 2010-05-18 | Allergy Therapeutics Limited | Allergen formulation |
US7815920B2 (en) | 1998-09-21 | 2010-10-19 | Allergy Therapeutics (UK) Ltd | Method of preparing an antigen-containing formulation |
EP1964573A2 (en) | 1999-10-22 | 2008-09-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
GB2360210B (en) * | 2000-01-14 | 2004-12-15 | Allergy Therapeutics Ltd | Sublingual vaccine formulation |
US8470331B2 (en) | 2000-01-14 | 2013-06-25 | Allergy Therapeutics (Uk) Limited | Composition of antigen and glycolipid adjuvant for sublingual administration |
GB2360210A (en) * | 2000-01-14 | 2001-09-19 | Allergy Therapeutics Ltd | Sublingual vaccine formulation |
US9597384B2 (en) | 2001-03-16 | 2017-03-21 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US8206701B2 (en) * | 2001-03-16 | 2012-06-26 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US9238063B2 (en) | 2001-03-16 | 2016-01-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundlheit und Umwelt (GmbH) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US8921534B2 (en) | 2001-12-12 | 2014-12-30 | Sanofi Pasteur Limited | Enhancement of the immune response using CD36-binding domain |
EP2356999A1 (en) * | 2003-06-17 | 2011-08-17 | Mannkind Corporation | Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
JP2013028619A (en) * | 2003-06-17 | 2013-02-07 | Mannkind Corp | Method to elicit, enhance and sustain immune response against mhc class i-restricted epitope, for prophylactic or therapeutic purpose |
WO2005002621A2 (en) * | 2003-06-17 | 2005-01-13 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
JP2007523863A (en) * | 2003-06-17 | 2007-08-23 | マンカインド コーポレイション | Methods for inducing, enhancing and maintaining an immune response against MHC class I restricted epitopes for prophylactic or therapeutic purposes |
WO2005002621A3 (en) * | 2003-06-17 | 2005-08-04 | Mannkind Corp | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
EP2246067A3 (en) * | 2003-06-17 | 2011-07-13 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
WO2006009919A3 (en) * | 2004-06-17 | 2006-04-27 | Mannkind Corp | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
WO2006009919A2 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
WO2006071989A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
WO2006071989A3 (en) * | 2004-12-29 | 2006-12-07 | Mannkind Corp | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
JP2008526763A (en) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | Methods for inducing, enhancing and retaining immune responses against MHC class I restricted epitopes for prophylactic or therapeutic purposes |
US9056080B2 (en) | 2005-04-14 | 2015-06-16 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US7795219B2 (en) | 2005-04-14 | 2010-09-14 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US7338670B2 (en) | 2005-04-14 | 2008-03-04 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US7790204B2 (en) | 2005-04-14 | 2010-09-07 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US8466110B2 (en) | 2005-04-14 | 2013-06-18 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US8198241B2 (en) | 2005-04-14 | 2012-06-12 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US20120039994A1 (en) * | 2006-09-26 | 2012-02-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US9987355B2 (en) | 2006-09-26 | 2018-06-05 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8840908B2 (en) | 2006-09-26 | 2014-09-23 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US9950063B2 (en) | 2006-09-26 | 2018-04-24 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US9907845B2 (en) | 2006-09-26 | 2018-03-06 | Infectious Disease Research Institute | Methods of using a vaccine composition containing synthetic adjuvant |
US10765736B2 (en) | 2006-09-26 | 2020-09-08 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8273361B2 (en) * | 2006-09-26 | 2012-09-25 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US10792359B2 (en) | 2006-09-26 | 2020-10-06 | Infectious Disease Research Institute | Methods of using a vaccine composition containing synthetic adjuvant |
US8343512B2 (en) * | 2006-09-26 | 2013-01-01 | Infectious Disease Research Institute | Treatment of allergic conditions using a composition containing synthetic adjuvant |
US11826417B2 (en) | 2007-07-02 | 2023-11-28 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US11369673B2 (en) | 2007-07-02 | 2022-06-28 | Etubics Corporation | HPV vaccines and methods of use thereof |
US11504423B2 (en) | 2007-07-02 | 2022-11-22 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US11529408B2 (en) | 2007-07-02 | 2022-12-20 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US11344613B2 (en) | 2007-07-02 | 2022-05-31 | Etubics Corporation | Sequential administration of a replication defective adenovirus vector in vaccination protocols |
US11376316B2 (en) | 2007-07-02 | 2022-07-05 | Etubics Corporation | Breast cancer vaccines and methods of use thereof |
US8298549B2 (en) | 2007-07-02 | 2012-10-30 | Etubics Corporation | Sequential administration of a replication defective adenovirus vector in vaccination protocols |
US11389521B2 (en) | 2007-07-02 | 2022-07-19 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US8697854B2 (en) | 2008-11-24 | 2014-04-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
US9862755B2 (en) | 2008-11-24 | 2018-01-09 | Max-Delbrueck-Centrum Fuer Molekulare Medizin | High affinity T cell receptor and use thereof |
US10626159B2 (en) | 2008-11-24 | 2020-04-21 | Max-Delbrueck-Centrum Fuer Molekulare Medizin | High affinity T cell receptor and use thereof |
US10632191B2 (en) | 2009-06-05 | 2020-04-28 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US9480740B2 (en) | 2009-06-05 | 2016-11-01 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US9814772B2 (en) | 2009-06-05 | 2017-11-14 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US9895435B2 (en) | 2012-05-16 | 2018-02-20 | Immune Design Corp. | Vaccines for HSV-2 |
US10563224B2 (en) | 2012-08-24 | 2020-02-18 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
US10342815B2 (en) | 2013-04-18 | 2019-07-09 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US8962593B2 (en) | 2013-04-18 | 2015-02-24 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US10993956B2 (en) | 2013-04-18 | 2021-05-04 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US8957047B2 (en) | 2013-04-18 | 2015-02-17 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US10064934B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
US10933127B2 (en) | 2015-10-22 | 2021-03-02 | Modernatx, Inc. | Betacoronavirus mRNA vaccine |
US10702599B2 (en) | 2015-10-22 | 2020-07-07 | Modernatx, Inc. | HPIV3 RNA vaccines |
US10702600B1 (en) | 2015-10-22 | 2020-07-07 | Modernatx, Inc. | Betacoronavirus mRNA vaccine |
US10543269B2 (en) | 2015-10-22 | 2020-01-28 | Modernatx, Inc. | hMPV RNA vaccines |
US10272150B2 (en) | 2015-10-22 | 2019-04-30 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
US11872278B2 (en) | 2015-10-22 | 2024-01-16 | Modernatx, Inc. | Combination HMPV/RSV RNA vaccines |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
Also Published As
Publication number | Publication date |
---|---|
ZA985460B (en) | 1999-01-26 |
WO1998058956A3 (en) | 1999-03-18 |
AU7983198A (en) | 1999-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998058956A2 (en) | Methods for inducing an immune response involving prime-boost protocols | |
Zwaveling et al. | Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides | |
Bocchia et al. | Antitumor vaccination: where we stand | |
US6426217B1 (en) | MAGE-3 peptides presented by HLA class II molecules | |
JP2019531090A (en) | Modified VSV-G and its vaccine | |
JP2015166388A (en) | Yeast-based therapeutic compositions as immunotherapy | |
JP2002515734A (en) | Immunostimulation mediated by genetically modified dendritic cells | |
AU2009326524A1 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
US8895017B2 (en) | HER-2 peptides and vaccines | |
ES2375948T3 (en) | PROCEDURE TO INCREASE THE SUBMISSION OF CLASS I OF ANTENDS? EXOGEN GENES BY CELLS DENDRÉ? TICAS HUMANAS. | |
AU2016303525A1 (en) | Modified yeast-Brachyury immunotherapeutic compositions | |
AU2003249357A1 (en) | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase | |
Hurpin et al. | The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity | |
JP2001517208A (en) | Therapeutic application of antigens or epitopes associated with damaged cell peptide processing, eg, expressed on RMA-S cells transformed with the B7-1 gene | |
WO2000052045A2 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
US20040241152A1 (en) | Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab | |
WO2000060055A1 (en) | Modified dendritic cells and uses therefor | |
Qu et al. | A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis | |
US6929792B1 (en) | Modified dendritic cells and use therefor | |
AU2014361788B2 (en) | Multi-epitope TARP peptide vaccine and uses thereof | |
Wang et al. | Covalent crosslinking of tumor antigens stimulates an antitumor immune response | |
JP4961706B2 (en) | HLA class II-restricted novel cancer antigen peptide | |
US20100310603A1 (en) | TEM8 as an Adjuvant and Uses Thereof | |
US20070253969A1 (en) | Materials and methods relating to DNA vaccination | |
Sfondrini | Enhancement of anti-tumour immunity by transduction with a Mycobacterium tuberculosis gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN JP KR NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN JP KR NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999504909 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |